展位97.1

Renovaro BioSciences公司 納斯達克規則5608
公司高級管理人員薪酬追回 政策

有效11月30日，2023

1.       政策 目的。這項Renovaro BioSciences Inc.納斯達克規則5608執行官薪酬收繳政策（以下簡稱「本」）的目的是使Renovaro BioSciences Inc.及其子公司和關聯公司（以下統稱「公司」）能夠在公司需要進行會計重述時追回錯誤授予的薪酬。本政策旨在遵守納斯達克股票市場有限責任公司的5608號上市規則，並將根據該目的進行解釋和解釋。除非本政策另有定義，否則首字母大寫的術語應按第7節所指定的含義來解釋。政策”）旨在使Renovaro BioSciences Inc.及其子公司和關聯公司（以下統稱「公司」）能夠在公司需要進行會計重述時追回錯誤授予的薪酬。本政策旨在遵守納斯達克股票市場有限責任公司的5608號上市規則，並將根據該目的進行解釋和解釋。除非本政策另有定義，否則首字母大寫的術語將按第7條規定的含義來解釋。公司）能夠在公司需要進行會計重述時追回錯誤授予的薪酬。本政策旨在遵守納斯達克股票市場有限責任公司的5608號上市規則，並將根據該目的進行解釋和解釋。除非本政策另有定義，否則首字母大寫的術語將按第7條規定的含義來解釋。

2.       政策 管理本政策將由董事會薪酬委員會（簡稱「委員會」）管理，除非董事會決定自行管理此政策。該委員會有權就本政策下的所有決定做出最終裁定，但須符合上市規則並遵守《美國內部收入法第409A條》的規定（或根據相關豁免）。該委員會根據本政策規定所作的所有決定和裁定將是最終的、確定的，並對所有人具有約束力，包括公司、其關聯公司、股東和高管。該委員會對本政策下的高管採取的任何行動或不作爲，並不限制該委員會根據本政策或任何類似政策、協議或安排對其他高管採取行動或不作爲，並且任何此類行動或不作爲也不構成公司對除本政策中規定之外的任何高管所擁有的權利的放棄。委員會所有決定和裁定委員會根據本政策的規定作出的，都將是最終的、確定的，並對所有人具有約束力，包括公司、其關聯公司、股東和高管。該委員會對本政策下的高管採取的任何行動或不作爲，並不限制該委員會根據本政策或任何類似政策、協議或安排對其他高管採取行動或不作爲，並且任何此類行動或不作爲也不構成公司對除本政策中規定之外的任何高管所擁有的權利的放棄。

3.       政策 應用本政策適用於在擔任高管過程中獲得激勵性報酬的任何人（a）在開始擔任高管後，（b）在激勵性報酬的績效期間內任職高管，（c）公司在某國家證券交易所或國家證券協會上市類別的證券交易所時，（d）在會計重述日期之前的三個已完成財政年度期間。除了最後那三個已完成財政年度之外，立刻前述的子句（d）包括由於公司財政年度在這三個已完成財政年度內或後即將變更而導致的任何過渡期，前提是公司上一個財政年度結束日和新財政年度開始日之間構成的九到十二個月的過渡期將被視爲一個完成的財政年度。對於本第3部分的目的，在實現激勵性報酬獎勵中指定的財務報告指標的公司財政期間內被認爲接受了激勵性報酬，即使激勵性報酬的支付或授予發生在該期間結束後。爲避免疑義，同時受財務報告指標歸屬條件和服務歸屬條件約束的激勵性報酬，在相關財務報告指標實現時被視爲接受，即使該激勵性報酬繼續受服務歸屬條件約束。

4.       政策 恢復要求在發生會計重述的情況下，公司必須合理迅速地追回因本政策確定的錯誤授予的報酬。公司追回因錯誤授予的報酬而產生的義務與公司是否以及何時提交重述財務報表無關。根據本政策，對於執行官的追回不需要發現任何執行官的不當行爲，也不需要發現該執行官因導致會計重述的會計錯誤而被認定爲有過錯。在發生會計重述的情況下，公司將通過行使其唯一和絕對酌情權來履行根據本政策從任何適用的執行官追回的任何欠款，只要符合交易所規則並遵守《法典》第409A條款或根據（或根據豁免）適用的規定進行的合規。根據本第4條的公司追回義務，不適用於當委員會，或在沒有委員會的情況下，任職於董事會的獨立董事的大多數裁定發現這種追回是不切實際的情況下：

a. 付款給第三方以協助執行本政策的直接費用將超過要收回的金額。在得出無法收回任何錯誤授予的補償金額的結論之前，公司必須盡力收回這些錯誤授予的補償金額，記錄這些合理的收回嘗試並向交易所提供該文件;

b. 恢復 將違反家庭國家法律，該法律是在2022年11月28日之前通過的。在得出基於家庭國家法律違反而無法收回任何錯誤授予的補償金額的結論之前，公司必須獲得交易所認可的家庭國家律師意見，證明收回將導致違反， 並必須向交易所提供該意見；或

c. 恢復 可能會導致一個本應符合稅收合格的養老計劃，在該計劃下，福利廣泛地提供給註冊人員員工，無法達到《法典》第401(a)(13)或411(a)條的要求。

5.       保單 禁止賠償和保險報銷公司禁止對任何現任或前任執行官賠償錯誤授予的薪酬損失。此外，公司不得支付或報銷執行官購買保險以覆蓋任何此類損失。

6.       必需 與政策相關的申報公司將根據聯邦證券法的要求提交與該政策相關的所有披露，包括美國證券交易委員會要求的披露文件。

7.       定義.

a. “會計重新陳述”是由於公司未遵守任何證券法規定的財務報告要求而進行的會計重述，包括任何必要的會計重述以糾正之前已發佈的財務報表中的錯誤，該錯誤對之前已發佈的財務報表具有重大影響，或者如果本期糾正錯誤或本期不糾正錯誤將導致重大誤報。

b.       “Accounting Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if the Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

c.       “Board” means the board of directors of the Company.

d.       “Code” means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.

e.       “Erroneously Awarded Compensation” means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Executive Officer. Notwithstanding the foregoing, for Incentive-Based Compensation based on stock price or total stockholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the Stock Exchange.

f.       “Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function or any other person who performs similar policy-making functions for the Company. An executive officer of the Company’s parent or subsidiary is deemed an “Executive Officer” if the executive officer performs such policy making functions for the Company.

g.       “Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measure, provided that a Financial Reporting Measure is not required to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a “Financial Reporting Measure.” For purposes of this Policy, “Financial Reporting Measure” includes, but is not limited to, stock price and total stockholder return.

h.       “Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

i.       “Stock Exchange” means the national stock exchange on which the Company’s common stock is listed.

8.       Acknowledgement. Each Executive Officer will sign and return to the Company, within 30 calendar days following the later of (i) the effective date of this Policy first set forth above or (ii) the date the individual becomes an Executive Officer, the Acknowledgement Form attached as Exhibit A, pursuant to which the Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.

9.       Severability. The provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and will automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.

10.     Amendment and Termination. The Board may amend this Policy from time to time in its sole and absolute discretion and will amend this Policy as it deems necessary to reflect the Listing Rule, to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this Policy at any time.

11.     Other Recovery Obligations and General Rights. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company recovers pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, the amount the relevant Executive Officer has already reimbursed the Company will be credited to the required recovery under this Policy. This Policy will not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case to the extent permitted under the Listing Rule and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. Nothing contained in this Policy will limit the Company’s ability to seek recoupment, in appropriate circumstances (including circumstances beyond the scope of this Policy) and as permitted by other applicable law, of any amounts from any individual, in each case to the extent permitted under the Listing Rule and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.

12.     Successors. This Policy is binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.

13.     Governing Law and Venue. This Policy and all rights and obligations hereunder are governed by and construed in accordance with the internal laws of the State of Delaware, excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction.

EXHIBIT A

Renovaro BioSciences Inc. NASDAQ RULE 5608
EXECUTIVE OFFICER Compensation CLAWBACK Policy

Acknowledgement Form

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Renovaro BioSciences Inc. Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy (the “Policy”).

By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment with Renovaro BioSciences Inc. and, as applicable, its subsidiaries and affiliates (the “Company”). Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.

Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy - Acknowledgement Form